[go: up one dir, main page]

MX2023010258A - Biomarcadores para la terapia del cancer usando antagonistas de mdm2. - Google Patents

Biomarcadores para la terapia del cancer usando antagonistas de mdm2.

Info

Publication number
MX2023010258A
MX2023010258A MX2023010258A MX2023010258A MX2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A
Authority
MX
Mexico
Prior art keywords
pathway
biomarkers
ddr
cancer
mdm2 antagonist
Prior art date
Application number
MX2023010258A
Other languages
English (en)
Inventor
Harpreet Kaur Saini
Nicola Ferrari
Jong Sook Ahn
Jessica Laura Brothwood
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2023010258A publication Critical patent/MX2023010258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona genes de la vía de respuesta por daño al ADN (DDR) y sus productos génicos como biomarcadores para predecir el tratamiento efectivo del cáncer usando un antagonista de MDM2. La identificación de uno o más biomarcadores de la vía de DDR en un paciente con cáncer permite determinar si es probable que el cáncer del paciente se trate con éxito usando un antagonista de MDM2. Por consiguiente, la invención se relaciona en general con un diagnóstico acompañante para la terapia con antagonistas de MDM2. En particular, la vía de DDR comprende uno o más genes de: la vía de reparación de recombinación homóloga (HRR); la vía de unión de extremos no homólogos (NHEJ); la vía de reparación de incompatibilidades (MMR); la vía de anemia de Fanconi (FA); y/o la vía de reparación por escisión de base (BER).
MX2023010258A 2021-03-04 2022-03-04 Biomarcadores para la terapia del cancer usando antagonistas de mdm2. MX2023010258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2103080.4A GB202103080D0 (en) 2021-03-04 2021-03-04 Cancer biomarkers
PCT/IB2022/051906 WO2022185260A1 (en) 2021-03-04 2022-03-04 Biomarkers for cancer therapy using mdm2 antagonists

Publications (1)

Publication Number Publication Date
MX2023010258A true MX2023010258A (es) 2023-09-12

Family

ID=75339986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010258A MX2023010258A (es) 2021-03-04 2022-03-04 Biomarcadores para la terapia del cancer usando antagonistas de mdm2.

Country Status (13)

Country Link
US (1) US20240293364A1 (es)
EP (1) EP4301875A1 (es)
JP (1) JP2024508895A (es)
KR (1) KR20230150285A (es)
CN (1) CN117295825A (es)
AU (1) AU2022230312A1 (es)
BR (1) BR112023017572A2 (es)
CA (1) CA3205532A1 (es)
GB (1) GB202103080D0 (es)
IL (1) IL304375A (es)
MX (1) MX2023010258A (es)
TW (1) TW202302087A (es)
WO (1) WO2022185260A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US20250114329A1 (en) * 2022-01-11 2025-04-10 Ascentage Pharma (Suzhou) Co., Ltd Methods for treating aml-mrc and mds
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
WO2025104679A1 (en) * 2023-11-16 2025-05-22 Otsuka Pharmaceutical Co., Ltd. Processes for making intermediates for isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AU2010319595B2 (en) 2009-11-12 2015-09-17 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
WO2011058367A2 (en) * 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
CN105026370B (zh) 2013-02-21 2017-11-10 霍夫曼-拉罗奇有限公司 取代的吡咯烷‑2‑甲酰胺的不对称合成
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US20160136280A1 (en) 2013-06-24 2016-05-19 Hoffmann-La Roche Inc. Stable intravenous formulation
JP6368311B2 (ja) 2013-09-04 2018-08-01 第一三共株式会社 スピロオキシインドール誘導体の製造方法
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
MX373045B (es) 2014-04-17 2020-05-26 Univ Michigan Regents Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3050645A1 (en) * 2018-07-27 2020-01-27 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
WO2020169073A1 (en) * 2019-02-24 2020-08-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
WO2022185260A1 (en) 2022-09-09
CA3205532A1 (en) 2022-09-09
KR20230150285A (ko) 2023-10-30
TW202302087A (zh) 2023-01-16
BR112023017572A2 (pt) 2023-10-10
US20240293364A1 (en) 2024-09-05
JP2024508895A (ja) 2024-02-28
CN117295825A (zh) 2023-12-26
AU2022230312A9 (en) 2025-03-13
GB202103080D0 (en) 2021-04-21
EP4301875A1 (en) 2024-01-10
IL304375A (en) 2023-09-01
AU2022230312A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MX2023010258A (es) Biomarcadores para la terapia del cancer usando antagonistas de mdm2.
Espinosa-Carrasco et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Pilger et al. Interfaces between cellular responses to DNA damage and cancer immunotherapy
Daniel et al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities
Wolcott et al. Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing
Hiley et al. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
Ali et al. Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
Zheng et al. Pathogenic and targetable genetic alterations in resected recurrent undifferentiated pleomorphic sarcomas identified by targeted next-generation sequencing
Zheng et al. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B‐cell lymphoma
Salerno et al. T cells in the human metastatic melanoma microenvironment express site‐specific homing receptors and retention integrins
Cortés et al. New approach to cancer therapy based on a molecularly defined cancer classification
Sousa et al. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells
WO2013192423A3 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
Dubey et al. Update in lung cancer 2008
Basak et al. Evidence for cell-free nucleic acids as continuously arising endogenous DNA mutagens
Goh et al. Presence and prevalence of UV related genetic mutations in uveal melanoma: similarities with cutaneous melanoma.
Perram et al. Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
Oda et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies
Heeke et al. Prevalence of homologous recombination deficiency (HRD) among all tumor types
Patchett et al. The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines
McCarthy et al. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients
Fleming et al. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma
Chang et al. Genomic landscapes of acral melanomas in East Asia
Thomas et al. Systemic treatment of penile squamous cell carcinoma—Hurdles and hopes of preclinical models and clinical regimens: A narrative review